KOREA WHO

Lee Gwan-sun is the CEO of Myungin Pharm. He leads the company as co-CEO with Cha Bong-kwon, president in charge of sales.

He was born on January 10, 1960, in Seosan, South Chungcheong Province.

He graduated from Daejeon High School in South Chungcheong Province and Seoul National University’s College of Education, where he majored in chemistry education.

He earned a master’s degree and a doctorate from the Department of Chemistry at KAIST (Korea Advanced Institute of Science and Technology).

He joined Hanmi Pharmaceutical and worked as head of the research institute and president of the R&D division. In 2010, he was appointed CEO and president, and later served as vice chairman for global strategy, leading the development of Hanmi Pharmaceutical’s new drug pipeline for 38 years.

In 2023, he founded GID Partners to support bio-company consulting and business strategy.

He served as co-chairman of Daewoong Pharmaceutical’s Research and Development (R&D) Committee.

In 2026, he was recruited as CEO of Myungin Pharm.

He is a new drug development expert who wrote the legend of Hanmi Pharmaceutical’s technology exports worth several trillion won.

He aims to transform Myungin Pharm from a generic drugmaker into a global new drug company centered on R&D (research and development).

He served as chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association and as the first chairman of the Lim Sung-ki Foundation.

#LeeGwan-sun #MyunginPharm #HanmiPharmaceutical #newdrugdevelopment #R&D #KAIST #DaewoongPharmaceutical #KPBMA #LimSungkiFoundation #pharmaceuticalindustry